RenovoRx, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2022. RenovoRx is a clinical-stage biopharmaceutical company developing local solid-tumor therapies; it reported no product revenue.
Financial performance and liquidity
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $1.390m | $0.536m | $2.679m | $1.170m |
| General and administrative expense | $1.224m | $0.330m | $2.940m | $0.749m |
| Total operating expenses | $2.614m | $0.866m | $5.619m | $1.919m |
| Net loss | $2.594m | $1.310m | $5.597m | $2.458m |
| Basic and diluted loss per share | $0.29 | $0.57 | $0.62 | $1.09 |
- Operating margins are not meaningful because the company had no revenue and incurred operating losses.
- At June 30, 2022, cash and cash equivalents were $2.769m and short-term U.S. Treasury securities were $7.996m, for approximately $10.8m in combined liquidity, versus $15.2m at December 31, 2021. Total assets were $11.243m; total liabilities were $1.123m; stockholders’ equity was $10.120m.
- Six-month operating cash use was $4.458m. Investing cash use was $8.000m, primarily Treasury bill purchases; financing provided $0.035m from option exercises. The resulting decrease in cash and cash equivalents was $12.423m; the Treasury purchases shifted funds into marketable securities.
- The filing reports no outstanding debt at June 30, 2022. Convertible notes had converted in connection with the 2021 IPO. The company has no credit facility or committed financing source.
Changes versus the prior comparable periods
- Q2 operating expenses rose 202% year over year; six-month expenses rose 193%. Higher clinical and preclinical development, regulatory and quality-assurance work, personnel, public-company costs, consulting and directors’ and officers’ insurance contributed to the increases.
- Q2 net loss increased by $1.284m, and the six-month net loss increased by $3.139m. The 2022 periods benefited from the absence of prior-year convertible-note interest and derivative-related expense; the 2021 six-month period also included a $0.140m PPP loan-forgiveness gain.
- Loss per share was lower despite higher net losses, largely alongside substantially higher weighted-average shares following the 2021 IPO and related share conversions.
Outlook, developments and risks
- Management said cash and investments available as of August 12, 2022 were expected to fund operating, investing and financing needs for at least 12 months, assuming programs advance as planned. The company expects continued and increasing losses and will need additional capital; financing may not be available on acceptable terms.
- The lead candidate, RenovoGem, is being studied in the Phase 3 TIGeR-PaC pancreatic cancer trial. The protocol had been changed to allow SBRT during induction rather than SBRT or IMRT. A modified statistical analysis plan submitted to FDA in June 2022 proposed analyzing SBRT patients only, adding a second interim analysis, reducing the planned randomized SBRT population from 200 to 114, and reducing statistical power from 90% to 80%. FDA agreement was not assured. As of August 10, 37 of the planned 114 SBRT patients had been randomized; management anticipated enrollment completion in 2024 and a final readout in 2025.
- The company submitted a protocol for a proposed Phase 2/3 RenovoGem trial in extrahepatic cholangiocarcinoma and anticipated a first patient in Q4 2022 if FDA did not object. These are forward-looking targets, not guarantees.
- Management cited clinical enrollment and retention, trial execution and regulatory approval, dependence on third-party manufacturers and a single-source RenovoCath supply, competition, and access to capital as significant risks. COVID-19 had affected trial recruitment and patient visits; the company reported no material supply-chain disruption to date. Inflation, workforce costs, and geopolitical uncertainty were additional stated risks.
- Disclosure controls were deemed ineffective because of a previously identified material weakness in financial reporting controls, including insufficient accounting expertise, formal procedures, management review and segregation of duties. Management was implementing remediation measures and intended to complete them during 2022; effectiveness had not yet been established.
- The filing reported no material legal proceedings, contractual obligations or off-balance-sheet arrangements. A $4,000 unrealized loss on available-for-sale Treasury securities was recorded in other comprehensive loss.
Most important facts for investors to verify
- Whether the FDA accepts the proposed TIGeR-PaC protocol and statistical plan, and whether enrollment and interim-analysis timing remain on track.
- Actual cash burn and remaining liquidity relative to management’s 12-month runway estimate, including the timing and terms of any new financing.
- Whether the planned eCCA trial begins and enrolls as anticipated, and whether RenovoCath supply and manufacturing arrangements support trial needs.
- Progress in remediating the material weakness and whether disclosure controls become effective.
- Clinical outcomes and their limitations: the filing’s cited 27.9-month median survival came from earlier Phase 1/2 and observational studies, which did not prospectively control prior standard-of-care treatment and are not equivalent to randomized Phase 3 evidence.